Ibogaine by David Dardashti Explores Groundbreaking Research Linking Genetic Enhancers to Neurological Disease Treatment, Including Parkinson's
The study utilized advanced genomic techniques, including CAGE, NET-CAGE, and Capture Hi-C/HiCap, to identify and characterize thousands of enhancers – non-coding DNA regions that play a crucial role in gene regulation – active during neuronal differentiation. Crucially, the researchers discovered a significant enrichment of genetic variants (SNPs) associated with Parkinson's disease and schizophrenia within these enhancers. This finding suggests that these enhancers, and the genes they regulate, are directly implicated in the development and progression of these conditions.
David Dardashti, a prominent advocate for ibogaine research, recognizes the profound implications of this study for the field of ibogaine therapy. 'This research provides a critical piece of the puzzle in understanding how ibogaine may exert its remarkable effects,' Dardashti explains. 'By demonstrating the direct involvement of specific genetic enhancers in neurological disorders, it opens up exciting new avenues for exploring ibogaine's mechanism of action at a molecular level.'
Ibogaine has shown promise in anecdotal reports and preliminary studies for its ability to alleviate symptoms of neurological conditions, including addiction, and potentially Parkinson's. Its purported anti-aging and restorative properties have also garnered significant interest. While the exact mechanisms remain under investigation, one hypothesis centers on ibogaine's potential to influence gene expression, possibly through interactions with these very enhancers identified in the EMBO Reports study.
The study's focus on LUHMES cells, a model for human dopaminergic neurons (the cells primarily affected in Parkinson's disease), is particularly relevant. By linking specific enhancers to genes involved in neuronal differentiation and disorders, the research provides a potential roadmap for understanding how ibogaine might influence these crucial cellular processes.
Dardashti is particularly intrigued by the potential connection between the identified genetic enhancers and the 'genetic rejuvenating factors' hypothesized to be influenced by ibogaine. 'If ibogaine can modulate the activity of these enhancers, which are clearly linked to neurological health and disease, it could explain its reported ability to promote neuroplasticity, reduce neuroinflammation, and potentially even reverse some of the cellular damage associated with conditions like Parkinson's,' he notes.
The research highlights the 'vast regulatory potential embedded in non-coding regions' of the genome. This aligns with the emerging understanding of ibogaine's potential to induce broad-spectrum changes in gene expression, leading to long-lasting therapeutic effects.
Ibogaine by David Dardashti is committed to rigorously examining the findings of this and other related studies. This deeper dive will help determine, specifically the implications for ibogaine treatment protocols and future research directions. The goal is to move beyond anecdotal evidence and establish a solid scientific foundation for ibogaine's use in treating neurological disorders, including the potential for mitigating the progression of Parkinson's disease.
About Ibogaine by David Dardashti:
Ibogaine by David Dardashti is dedicated to exploring the therapeutic potential of ibogaine and promoting responsible research into its applications for addiction, neurological disorders, and overall well-being.
Media Contact
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
5 hours ago
- Business Insider
Medtronic Stock (MDT) Slides Despite Corporate Re-Jig to Boost Ailing Valuation
Shares in medical technology group Medtronic (MDT) lost ground today after a corporate reshuffle aimed at boosting M&A. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to a report in the Wall Street Journal, activist investor Elliott Investment Management has become one of the group's largest shareholders. This followed a series of so-called friendly talks between the pair focused on boosting the company's valuation – currently $119 billion – and how to concentrate on core assets. The exact size of Elliott's previously undisclosed stake is not known. Veteran Directors It is understood that when Medtronic announces its first quarter results later on Tuesday, August 19, it will reveal that veteran med-tech executives John Groetelaars and Bill Jellison will be joining its board as independent directors. It is also expected to detail the formation of new special committees focused on growth and operations that will include the new directors and be led by Medtronic chief executive Geoff Martha. One of the new committees will look for so-called tuck-in M&A opportunities, research and development investments and potential divestitures. The other will look for ways to boost earnings growth. Undervalued Stock Medtronic develops, manufactures and distributes medical devices and therapies that treat more than 70 health conditions, from Parkinson's to diabetes. The company, which is based in Ireland but has its operational headquarters in Minneapolis, has seen its shares rise more than 16% so far this year. However, the company is still seen as undervalued, especially for being the biggest med-tech company globally by revenue. Medtronic booked more than $32 billion in revenue in 2024. In comparison Boston Scientific (BSX), with a larger market value of almost $153 billion, reported about $17 billion in sales last year. Its share price performance is also trailing. The company has already been making moves to boost its value. It has focused on innovations such as how to treat atrial fibrillation, which has been a huge growth spot in the industry. It is also planning a separation of its diabetes business into a stand-alone group. Is MDT a Good Stock to Buy Now? On TipRanks, MDT has a Moderate Buy consensus based on 13 Buy, 12 Hold and 1 Sell ratings. Its highest price target is $109. MDT stock's consensus price target is $98.44, implying a 6.07% upside. See more MDT analyst ratings
Yahoo
20 hours ago
- Yahoo
Not just a garnish! The herb that can help shed water weight and relieve bloating
Parsley is often served as a garnish, alongside a roast chicken or on a steaming plate of spaghetti. But, with its rough texture and slightly bitter taste, many may not consider the herb to be a crucial part of their diet. Still, parsley is more than meets the eye, and experts say it can help to regulate your digestive health. 'It can help aid in digestion and help reduce bloating,' Amanda Capriglione, a registered dietitian, told The Healthy. 'It contains compounds that enable the expulsion of gas from the body.' Cultivated for thousands of years, the ancient Mediterranean plant is what is known as a natural diuretic. Diuretics are substances that help us to shed excess water weight and salt. Some others include dandelions, caffeine, and a variety of fruits and vegetables. A sprinkle of parsley in a tabouleh salad, green smoothie, or vegetable soup can be enough to make a difference. Just make sure it won't conflict with any medication you're on, and talk to your doctor if you're pregnant, as it could lead to abortion, according to past research. 'Incorporate herbs into your diet via a meal, not in a pill or liquid concentrated form,' Julia Zumpano, a registered dietitian, told the Cleveland Clinic. Parsley is also rich in flavones, which are a type of plant-based compounds that have anti-inflammatory benefits. Inflammation can result in autoimmune, neurodegenerative, gastrointestinal, and heart diseases, as well as certain cancers. Together, inflammatory diseases account for more than half of all deaths globally, according to the Clinic. Furthermore, the plant is high in antioxidants, which are substances — including vitamins — that can help to prevent or slow damage to our body's cells. Parsley contains vitamins C, A, and E, which can help reduce inflammation that could result in chronic disease. Eating parsley 'can help reduce the risk of arthritis, an inflammation of the joints,' Dr. Brunilda Nazario, the lead medical director for WebMD, told The Healthy. 'It is also an excellent source of flavonoids, antioxidants that help reduce the risk of many chronic diseases, including cancer, atherosclerosis, Alzheimer's, and Parkinson's disease.' If you're looking to fortify you bone health, parsley is also good source of vitamin K. Including vitamin K in your diet can do just that. Adult women need 90 micrograms of the vitamin a day, and men need 120, according to the National Institutes of Health. 'Ten sprigs of parsley is enough to reach your daily dose of vitamin K,' Capriglione said.
UPI
2 days ago
- UPI
FDA approves ketamine product for surgical pain management
The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management. Ketamine is the only psychedelic or psychedelic-adjacent drug on the World Health Organization Essential Medicines List, with its global market projected to grow from $750 million to $3.42 billion by 2034. PharmaTher, which developed KETARx, believes there is a promising outlook for the ketamine market and that the FDA approval provides a strong foundation for expanding the development of ketamine across diverse therapeutic areas. These areas include depression, neurological disorders (Parkinson disease, amyotrophic lateral sclerosis), and rare or chronic pain conditions. "Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for PharmaTher is a testament to years of dedicated development, signaling a new era of growth," Fabio Chianelli, founder and CEO of PharmaTher, said in a statement. "We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders." Approval of KETARx was granted to PharmaTher. More Information Copyright © 2025 HealthDay. All rights reserved.
